Opinion
Video
Author(s):
The panel concludes with perspectives on the future of treatment for patients with colorectal cancer, including unmet needs in the disease space.
OncLive’s May Roundup of Key FDA Approvals in Oncology
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
FDA Advisory Committee Recommends Approval of Shield Blood Test for CRC Detection in Average-Risk Adults
FDA Approval Insights: Ponatinib in Ph+ ALL
FDA to Hold End-of-Phase 2 Meeting for Botensilimab Plus Balstilimab in R/R mCRC
Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy
Dr Grünwald on Examining Progression Patterns for Lenvatinib Plus Pembrolizumab in Advanced RCC
Dr Gerds on Updated Data for Pelabresib Plus Ruxolitinib in JAK Inhibitior–Naive Myelofibrosis
Asciminib Bests Standard-of-Care TKIs in Ph+ CML
Lorlatinib Yields Longest Reported PFS in Advanced ALK+ NSCLC